Dr. Lyudmila Sarder Receives Rave Reviews from Lakeland Regional Health and AdventHealth Cancer Institute for Research
Laekland Regional Health
Laekland Regional Health

❝The commendable efforts of Dr. Lyudmila Sarder and Dr. Sarfraz Ahmad in combating the financial barriers associated with cancer treatment offer hope to patients and their families. The physicians’ ultimate goal is to pave the way for a more equitable healthcare system that provides cost-effective treatments to those who need them the most.❞

Lakeland, FL, Aug. 21, 2023 (GLOBE NEWSWIRE) -- AdventHealth Cancer Institute proudly unveiled findings that mark a significant milestone in the cancer research field. Meanwhile, Lakeland Regional Health takes great pride in their resident physician who played a pivotal role in the research.


Photo: Dr. Lyudmila Sarder, MD, Resident Physician at Lakeland Regional Health, with Dr. Luis Daniel Lugo, MD, Program Director, Internal Medicine, Lakeland Regional Health | Lakeland, Florida 

Dr. Lyudmila Sarder, a Resident Physician at Lakeland Regional Health in Florida, and Dr. Sarfraz Ahmad, who is the Director of Clinical Research at the Gynecologic Oncology Department at AdventHealth Cancer Institute, collaborated to shed light on the emerging role of biosimilars in the treatment of HER2-positive breast cancer. The publication of their research in ScienceDirect, a prestigious journal published by Elsevier, focuses on the efficacy and safety of biosimilars, specifically in relation to trastuzumab, the first oncogene-targeted therapeutic agent for solid tumors.

The number of breast cancer cases, particularly among females, has sharply increased worldwide. HER2-positive breast cancer, characterized by the overexpression of the human epidermal growth factor receptor-2 protein, is known to be more aggressive than typical breast cancer. Trastuzumab, marketed under the brand name Herceptin, has revolutionized the treatment landscape for this specific type of breast cancer.

However, the high cost associated with trastuzumab has posed a significant barrier to patients in need, an issue that biosimilars may address. Biosimilars are medications that closely resemble biologics in terms of safety and efficacy, providing a more affordable alternative without compromising on quality.

Photo: Dr. Lyudmila Sarder, MD, Resident Physician at Lakeland Regional Health with Dr. Sarfraz Ahmad, PhD, Director of Clinical Research at the Gynecologic Oncology Department at AdventHealth Cancer Institute | Orlando, Florida 

Dr. Sarder and Dr. Ahmad's research highlights the potential of biosimilars to alleviate the financial burden faced by cancer patients. By offering a cost-effective option, biosimilars have the power to improve patient outcomes and enhance accessibility to life-saving treatments.